Investigational drug · Phase 2
TAR-0520
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hand and Foot Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "TAR-0520"
First trial start
2026
Mar 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TAR-0520", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hand and Foot Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "TAR-0520" as an intervention, largest first.
Tarian PharmaIndustry
NCT06818058 · 60 participants (planned) · Start Jan 20, 2025 · Primary completion Sep 1, 2026
Drug: Brimonidine tartrate Gel; Placebo gel (no Brimonidine tartrate) · For: EGFR Inhibitor-associated Rash
Sites: Lyon, France; Marseille, France; Nice, France
- Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral NeuropathyNot yet recruiting
Tarian PharmaIndustry
NCT07082764 · 30 participants (planned) · Start Sep 1, 2025 · Primary completion Sep 30, 2026
Drug: Brimonidine gel · For: Chemotherapy Induced Peripheral Neuropathy
Sites: Marseille, France
- TAR-0520 Gel in Hand and Foot SyndromeNot yet recruiting
Tarian PharmaIndustry
NCT07457671 · 25 participants (planned) · Start Mar 2026 · Primary completion Mar 2027
Drug: TAR-0520 gel · For: Hand and Foot Syndrome
Sites: Marseille, France
Newest research
PubMed records naming it or its code names, newest first.
- TAR-0520, a new candidate in oncodermatology: Results of a phase 1 program in healthy volunteers.
Andres P, Winckle G, Lamquin A, et al. · Support Care Cancer 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.